TY - JOUR
T1 - Overcoming obstacles in microRNA delivery towards improved cancer therapy
AU - Ben-Shushan, Dikla
AU - Markovsky, Ela
AU - Gibori, Hadas
AU - Tiram, Galia
AU - Scomparin, Anna
AU - Satchi-Fainaro, Ronit
N1 - Funding Information:
We would like to thank Dr Noga Yerushalmi for critical appraisal of the manuscript. The Satchi-Fainaro research laboratory is partially supported by The Association for International Cancer Research (AICR), German-Israel Foundation (GIF), The Marguerite Stolz Research Fund for outstanding faculty, Rimonim Consortium and the MAGNET Program of the Office of the Chief Scientist of the Israel Ministry of Industry, Trade & Labor, THE ISRAEL SCIENCE FOUNDATION (grant no. 1309/10), the US–Israel Binational Science Foundation (grant no. 2007347), Swiss Bridge Award, and by grants from the Israeli National Nanotechnology Initiative (INNI), Focal Technology Area (FTA) program: Nanomedicine for Personalized Theranostics, and by The Leona M. and Harry B. Helmsley Nanotechnology Research Fund.
PY - 2014/2
Y1 - 2014/2
N2 - MicroRNAs (miRNAs) are small noncoding RNAs found to govern nearly every biological process. They frequently acquire a gain or a loss of function in cancer, hence playing a causative role in the development and progression of cancer. There are major obstacles on the way for the successful delivery of miRNA, which include low cellular uptake of the RNA and endosomal escape, immunogenicity, degradation in the bloodstream, and rapid renal clearance. The delivered miRNA needs to be successfully routed to the target organ, enter the cell and reach its intracellular target in an active form. Consequently, in order to exploit the promise of RNA interference, there is an urgent need for efficient methods to deliver miRNAs. These can be divided into three main categories: complexation, encapsulation, and conjugation. In this review, we will discuss the special considerations for miRNA delivery for cancer therapy, focusing on nonviral delivery systems: lipid, polymeric, and inorganic nanocarriers.
AB - MicroRNAs (miRNAs) are small noncoding RNAs found to govern nearly every biological process. They frequently acquire a gain or a loss of function in cancer, hence playing a causative role in the development and progression of cancer. There are major obstacles on the way for the successful delivery of miRNA, which include low cellular uptake of the RNA and endosomal escape, immunogenicity, degradation in the bloodstream, and rapid renal clearance. The delivered miRNA needs to be successfully routed to the target organ, enter the cell and reach its intracellular target in an active form. Consequently, in order to exploit the promise of RNA interference, there is an urgent need for efficient methods to deliver miRNAs. These can be divided into three main categories: complexation, encapsulation, and conjugation. In this review, we will discuss the special considerations for miRNA delivery for cancer therapy, focusing on nonviral delivery systems: lipid, polymeric, and inorganic nanocarriers.
KW - Cancer therapeutics
KW - Combination therapy
KW - Drug delivery systems
KW - RNAi
UR - http://www.scopus.com/inward/record.url?scp=84893529322&partnerID=8YFLogxK
U2 - 10.1007/s13346-013-0160-0
DO - 10.1007/s13346-013-0160-0
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:84893529322
SN - 2190-393X
VL - 4
SP - 38
EP - 49
JO - Drug Delivery and Translational Research
JF - Drug Delivery and Translational Research
IS - 1
ER -
